Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview 10 Therapeutics Development 11 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development 11 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area 12 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication 13 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies 17 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes 21 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 Amgen Inc. 30 Antisense Therapeutics Limited 31 Astellas Pharma Inc. 32 AstraZeneca Plc 33 Axelar AB 34 Boehringer Ingelheim GmbH 35 Eli Lilly and Company 36 F. Hoffmann-La Roche Ltd. 37 Genmab A/S 38 Immunomedics, Inc. 39 Insmed Incorporated 40 Merck & Co., Inc. 41 Merrimack Pharmaceuticals, Inc. 42 Novartis AG 43 PharmAbcine, Inc. 44 Prometheon Pharma, LLC 45 ProteoThera, Inc. 46 Silver Creek Pharmaceuticals, Inc. 47 Sucampo Pharmaceuticals, Inc. 48 TyrNovo Ltd. 49 XL-protein GmbH 50 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles 51 1R-15-15 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 1R-2b - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 1R-3s - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 1R-E1-E1 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 ATL-1101 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 AXL-1717 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 AZD-3463 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 BI-893923 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 CT-707 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 dalotuzumab - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 ganitumab - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Hex-hR1 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 istiratumab - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 lenaldekar - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 linsitinib - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 M-590 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 mecasermin rinfabate - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 NT-157 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 NT-219 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Protein to Agonize Insulin Like Growth Factor 1 Receptor for Hormone Replacement Therapy - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Recombinant Insulin Like Growth Factor 1 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Recombinant Protein to Antagonize IGF-1R for Oncology - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 RU-105 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecules to Antagonize IGF-1R for Oncology - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 Small Molecules to Inhibit IGF1R for Breast Cancer - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 teprotumumab - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 vesiculin - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 XGFR-2 - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 XGFR-4 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 XL-110 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects 100 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products 107 Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases 111 Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants 111 Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting 112 Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy 112 May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 113 Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 113 Mar 17, 2015: Study suggests precision medicine for adrenal cancer 115 Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 116 Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer 117 Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting 117 Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics 118 Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer 119 Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer 120 Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 120 Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 121 Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 121 Appendix 122 Methodology 122 Coverage 122 Secondary Research 122 Primary Research 122 Expert Panel Validation 122 Contact Us 122 Disclaimer 123
List of Tables
Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Pipeline by Amgen Inc., H2 2016 30 Pipeline by Antisense Therapeutics Limited, H2 2016 31 Pipeline by Astellas Pharma Inc., H2 2016 32 Pipeline by AstraZeneca Plc, H2 2016 33 Pipeline by Axelar AB, H2 2016 34 Pipeline by Boehringer Ingelheim GmbH, H2 2016 35 Pipeline by Eli Lilly and Company, H2 2016 36 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 37 Pipeline by Genmab A/S, H2 2016 38 Pipeline by Immunomedics, Inc., H2 2016 39 Pipeline by Insmed Incorporated, H2 2016 40 Pipeline by Merck & Co., Inc., H2 2016 41 Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 42 Pipeline by Novartis AG, H2 2016 43 Pipeline by PharmAbcine, Inc., H2 2016 44 Pipeline by Prometheon Pharma, LLC, H2 2016 45 Pipeline by ProteoThera, Inc., H2 2016 46 Pipeline by Silver Creek Pharmaceuticals, Inc., H2 2016 47 Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 48 Pipeline by TyrNovo Ltd., H2 2016 49 Pipeline by XL-protein GmbH, H2 2016 50 Dormant Projects, H2 2016 100 Dormant Projects (Contd..1), H2 2016 101 Dormant Projects (Contd..2), H2 2016 102 Dormant Projects (Contd..3), H2 2016 103 Dormant Projects (Contd..4), H2 2016 104 Dormant Projects (Contd..5), H2 2016 105 Dormant Projects (Contd..6), H2 2016 106 Discontinued Products, H2 2016 107 Discontinued Products (Contd..1), H2 2016 108 Discontinued Products (Contd..2), H2 2016 109 Discontinued Products (Contd..3), H2 2016 110
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
